开云app官网登录入口网页版-官方正版

#转移性尿路上皮癌#

35篇内容 | 1900人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2219226, encodeId=f15a22192263a, content=<a href='/topic/show?id=d1559341310' target=_blank style='color:#2F92EE;'>#转移性尿路上皮癌#</a> <a href='/topic/show?id=592a1e84415' target=_blank style='color:#2F92EE;'>#Trop-2#</a> <a href='/topic/show?id=07b7106393d5' target=_blank style='color:#2F92EE;'>#戈沙妥珠单抗#</a>, objectTitle=CLIN CANCER RES | Trop-2 在转移性尿路上皮癌患者中高表达，并可作为戈沙妥珠单抗治疗的潜在靶点, objectType=article, longId=838244, objectId=d0878382447c, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240808/1723129917368_6145188.jpg, objectUrl=/article/show_article.do?id=d0878382447c, replyNumber=0, likeNumber=47, createdTime=2024-08-09, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=d0878382447c, moduleTitle=CLIN CANCER RES | Trop-2 在转移性尿路上皮癌患者中高表达，并可作为戈沙妥珠单抗治疗的潜在靶点, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=d0878382447c)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2218535, encodeId=35b5221853559, content=<a href='/topic/show?id=94c265920c' target=_blank style='color:#2F92EE;'>#EGFR突变#</a> <a href='/topic/show?id=d1559341310' target=_blank style='color:#2F92EE;'>#转移性尿路上皮癌#</a> <a href='/topic/show?id=b0054454337' target=_blank style='color:#2F92EE;'>#奥希替尼#</a>, objectTitle=首例：携带EGFR突变的转移性尿路上皮癌获益奥希替尼五线治疗，获得长期缓解, objectType=article, longId=837576, objectId=5ad283e576e1, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240615/1718466649285_92910.png, objectUrl=/article/show_article.do?id=5ad283e576e1, replyNumber=0, likeNumber=49, createdTime=2024-08-05, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=5ad283e576e1, moduleTitle=首例：携带EGFR突变的转移性尿路上皮癌获益奥希替尼五线治疗，获得长期缓解, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=5ad283e576e1)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2188808, encodeId=6c3b2188808c4, content=在ARON-2真实世界研究(NCT05290038)的亚分析中，我们旨在评估同时使用<a href='/topic/show?id=02f99235e23' target=_blank style='color:#2F92EE;'>#质子泵抑制剂#</a>(PPI)、<a href='/topic/show?id=2f9525346ca' target=_blank style='color:#2F92EE;'>#他汀类药物#</a>或<a href='/topic/show?id=ce9d239823b' target=_blank style='color:#2F92EE;'>#二甲双胍#</a>对接受二线<a href='/topic/show?id=34b54848271' target=_blank style='color:#2F92EE;'>#帕博利珠单抗#</a>治疗的<a href='/topic/show?id=d1559341310' target=_blank style='color:#2F92EE;'>#转移性尿路上皮癌#</a>(mUC)患者预后的影响。这个解释从<a href='/topic/show?id=b1fd816e094' target=_blank style='color:#2F92EE;'>#肠道微生物#</a>角度，有些存疑。使用PPI的人群，往往都伴有消化道疾病，或反酸，这会影响到患者的生活质量，这类患者可能对治疗本身应答也可能会产生影响，并不一定就是药物本身。同样，二甲双胍在不少观察性研究中显示对肿瘤免疫治疗可能有获益，但是<a href='/topic/show?id=c3aa4e516d6' target=_blank style='color:#2F92EE;'>#尿路上皮癌#</a>治疗中，帕博利珠单抗的价值本身也有限，无法观察出协同效应也是正常的，但是并不代表在其它瘤种中有相似的结果。因此，在其它瘤种中，依然可以开展类似的研究，或进行meta分析, objectTitle=读书报告 | 应用帕博利珠单抗治疗转移性尿路上皮癌患者同时使用质子泵抑制剂、他汀类药物或二甲双胍对患者预后的影响, objectType=article, longId=814138, objectId=9ab28141389c, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/black-surgeon-giving-instruction-to-medical-team-TMPFGNZ.jpg, objectUrl=/article/show_article.do?id=9ab28141389c, replyNumber=0, likeNumber=81, createdTime=2024-02-23, rootId=0, userName=侠胆医心, userId=f63e4754896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=加利福尼亚, moduleDTOList=[ModuleDTO(moduleId=9ab28141389c, moduleTitle=读书报告 | 应用帕博利珠单抗治疗转移性尿路上皮癌患者同时使用质子泵抑制剂、他汀类药物或二甲双胍对患者预后的影响, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=9ab28141389c)], followStatus=false, userIsMember=false, type=1, lengthMark=1), GetTopicListResponse(id=2178612, encodeId=e5bd21e86125b, content=<a href='/topic/show?id=597725653fd' target=_blank style='color:#2F92EE;'>#伊匹单抗#</a> <a href='/topic/show?id=d1559341310' target=_blank style='color:#2F92EE;'>#转移性尿路上皮癌#</a> <a href='/topic/show?id=fc2be734870' target=_blank style='color:#2F92EE;'>#纳武利尤单抗#</a>, objectTitle=读书报告 | TITAN-TCC研究：含铂化疗后进展的尿路上皮癌患者接受定制的纳武利尤单抗联合伊匹木单抗免疫治疗的II期临床试验, objectType=article, longId=807722, objectId=92ce80e72221, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/doctor-in-his-practice-with-a-digital-tablet-UWZKVBN.jpg, objectUrl=/article/show_article.do?id=92ce80e72221, replyNumber=0, likeNumber=127, createdTime=2024-01-01, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=92ce80e72221, moduleTitle=读书报告 | TITAN-TCC研究：含铂化疗后进展的尿路上皮癌患者接受定制的纳武利尤单抗联合伊匹木单抗免疫治疗的II期临床试验, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=92ce80e72221)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1395052, encodeId=791113950521e, content=<a href='/topic/show?id=d1559341310' target=_blank style='color:#2F92EE;'>#转移性尿路上皮癌#</a>, objectTitle=J Clin Oncol：化疗后采用鲁卡帕尼维持治疗DNA修复缺陷阳性转移性尿路上皮癌, objectType=article, longId=736046, objectId=9162e3604691, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9162e3604691, replyNumber=0, likeNumber=93, createdTime=2022-08-18, rootId=0, userName=ms7019579240139182, userId=84182500174, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9162e3604691, moduleTitle=J Clin Oncol：化疗后采用鲁卡帕尼维持治疗DNA修复缺陷阳性转移性尿路上皮癌, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=9162e3604691)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1395051, encodeId=95191395051a4, content=<a href='/topic/show?id=d1559341310' target=_blank style='color:#2F92EE;'>#转移性尿路上皮癌#</a>, objectTitle=Eur Urol：Bempegaldesleukin加Nivolumab用于一线转移性尿路上皮癌效果如何？, objectType=article, longId=730487, objectId=eb89e30487a4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eb89e30487a4, replyNumber=0, likeNumber=106, createdTime=2022-06-27, rootId=0, userName=ms7019579240139182, userId=84182500174, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eb89e30487a4, moduleTitle=Eur Urol：Bempegaldesleukin加Nivolumab用于一线转移性尿路上皮癌效果如何？, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=eb89e30487a4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1395050, encodeId=7cc5139505008, content=<a href='/topic/show?id=d1559341310' target=_blank style='color:#2F92EE;'>#转移性尿路上皮癌#</a>, objectTitle=J Clin Oncol：杜瓦鲁单抗联合奥拉帕利治疗初治的转移性尿路上皮癌的疗效和安全性, objectType=article, longId=730446, objectId=7c9fe304466b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7c9fe304466b, replyNumber=0, likeNumber=93, createdTime=2022-06-26, rootId=0, userName=ms7019579240139182, userId=84182500174, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7c9fe304466b, moduleTitle=J Clin Oncol：杜瓦鲁单抗联合奥拉帕利治疗初治的转移性尿路上皮癌的疗效和安全性, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=7c9fe304466b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1395049, encodeId=ee8f1395049ce, content=<a href='/topic/show?id=d1559341310' target=_blank style='color:#2F92EE;'>#转移性尿路上皮癌#</a>, objectTitle=J Immunother Cancer：卡瑞利珠单抗联合法米替尼治疗铂类进展的晚期或转移性尿路上皮癌的疗效和安全性, objectType=article, longId=726649, objectId=3c23e2664918, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3c23e2664918, replyNumber=0, likeNumber=104, createdTime=2022-05-13, rootId=0, userName=ms7019579240139182, userId=84182500174, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3c23e2664918, moduleTitle=J Immunother Cancer：卡瑞利珠单抗联合法米替尼治疗铂类进展的晚期或转移性尿路上皮癌的疗效和安全性, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=3c23e2664918)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1395048, encodeId=15901395048f3, content=<a href='/topic/show?id=d1559341310' target=_blank style='color:#2F92EE;'>#转移性尿路上皮癌#</a>, objectTitle=NICE推荐Bavncio (avelumab)治疗局部晚期转移性尿路上皮癌 (UC), objectType=article, longId=724472, objectId=bbc0e244722a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bbc0e244722a, replyNumber=0, likeNumber=73, createdTime=2022-04-19, rootId=0, userName=ms7019579240139182, userId=84182500174, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bbc0e244722a, moduleTitle=NICE推荐Bavncio (avelumab)治疗局部晚期转移性尿路上皮癌 (UC), moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=bbc0e244722a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1395047, encodeId=c0d5139504e47, content=<a href='/topic/show?id=d1559341310' target=_blank style='color:#2F92EE;'>#转移性尿路上皮癌#</a>, objectTitle=Eur Urol：恩福单抗维多汀治疗局部晚期或转移性尿路上皮癌的疗效如何？, objectType=article, longId=299913, objectId=686d29991338, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=686d29991338, replyNumber=0, likeNumber=75, createdTime=2022-03-03, rootId=0, userName=ms7019579240139182, userId=84182500174, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=686d29991338, moduleTitle=Eur Urol：恩福单抗维多汀治疗局部晚期或转移性尿路上皮癌的疗效如何？, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=686d29991338)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1395046, encodeId=eaf0139504682, content=<a href='/topic/show?id=d1559341310' target=_blank style='color:#2F92EE;'>#转移性尿路上皮癌#</a>, objectTitle=Clin Cancer Res：采用卡博替尼联合纳武单抗治疗PCI难治性转移性尿路上皮癌, objectType=article, longId=295762, objectId=3cdc295e62fa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3cdc295e62fa, replyNumber=0, likeNumber=129, createdTime=2022-02-17, rootId=0, userName=ms7019579240139182, userId=84182500174, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3cdc295e62fa, moduleTitle=Clin Cancer Res：采用卡博替尼联合纳武单抗治疗PCI难治性转移性尿路上皮癌, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=3cdc295e62fa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1395045, encodeId=04df13950458d, content=<a href='/topic/show?id=d1559341310' target=_blank style='color:#2F92EE;'>#转移性尿路上皮癌#</a>, objectTitle=Clin Cancer Res：托瑞帕利单抗二线治疗转移性尿路上皮癌的疗效、安全性和生物标志物, objectType=article, longId=220114, objectId=de3b22011460, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=de3b22011460, replyNumber=0, likeNumber=108, createdTime=2021-11-12, rootId=0, userName=ms7019579240139182, userId=84182500174, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=de3b22011460, moduleTitle=Clin Cancer Res：托瑞帕利单抗二线治疗转移性尿路上皮癌的疗效、安全性和生物标志物, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=de3b22011460)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1395044, encodeId=6b39139504404, content=<a href='/topic/show?id=d1559341310' target=_blank style='color:#2F92EE;'>#转移性尿路上皮癌#</a>, objectTitle=Int J Urol：铂基一线化疗对转移性尿路上皮癌患者总生存的影响, objectType=article, longId=219077, objectId=4bf12190e736, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4bf12190e736, replyNumber=0, likeNumber=87, createdTime=2021-10-24, rootId=0, userName=ms7019579240139182, userId=84182500174, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4bf12190e736, moduleTitle=Int J Urol：铂基一线化疗对转移性尿路上皮癌患者总生存的影响, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=4bf12190e736)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1395043, encodeId=14dc139504395, content=<a href='/topic/show?id=d1559341310' target=_blank style='color:#2F92EE;'>#转移性尿路上皮癌#</a>, objectTitle=The Oncologist：转移性尿路上皮癌铂类为基础化疗进展后再挑战的疗效, objectType=article, longId=215461, objectId=9370215461b2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9370215461b2, replyNumber=0, likeNumber=84, createdTime=2021-08-10, rootId=0, userName=ms7019579240139182, userId=84182500174, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9370215461b2, moduleTitle=The Oncologist：转移性尿路上皮癌铂类为基础化疗进展后再挑战的疗效, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=9370215461b2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1395042, encodeId=b86c139504235, content=<a href='/topic/show?id=d1559341310' target=_blank style='color:#2F92EE;'>#转移性尿路上皮癌#</a>, objectTitle=Br J Cancer：转移性尿路上皮癌中FGFR3基因改变跟免疫检查点抑制剂应答的关系：真实世界研究, objectType=article, longId=214990, objectId=95022149908f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=95022149908f, replyNumber=0, likeNumber=119, createdTime=2021-07-30, rootId=0, userName=ms7019579240139182, userId=84182500174, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=95022149908f, moduleTitle=Br J Cancer：转移性尿路上皮癌中FGFR3基因改变跟免疫检查点抑制剂应答的关系：真实世界研究, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=95022149908f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1395041, encodeId=4c61139504119, content=<a href='/topic/show?id=d1559341310' target=_blank style='color:#2F92EE;'>#转移性尿路上皮癌#</a>, objectTitle=Lancet oncol：Enfortumab vedotin用于抗PD-1治疗后的铂不适用的局部晚期或转移性尿路上皮癌的疗效可期！, objectType=article, longId=211335, objectId=282e211335e4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=282e211335e4, replyNumber=0, likeNumber=67, createdTime=2021-05-16, rootId=0, userName=heli0118, userId=21015, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=282e211335e4, moduleTitle=Lancet oncol：Enfortumab vedotin用于抗PD-1治疗后的铂不适用的局部晚期或转移性尿路上皮癌的疗效可期！, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=282e211335e4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1395040, encodeId=a9bc1395040c9, content=<a href='/topic/show?id=d1559341310' target=_blank style='color:#2F92EE;'>#转移性尿路上皮癌#</a>, objectTitle=Eur Urol：铂治疗的局部晚期或转移性尿路上皮癌患者的Atezolizumab与化疗治疗比较 , objectType=article, longId=211015, objectId=27af21101554, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=27af21101554, replyNumber=0, likeNumber=95, createdTime=2021-05-11, rootId=0, userName=ms7019579240139182, userId=84182500174, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=27af21101554, moduleTitle=Eur Urol：铂治疗的局部晚期或转移性尿路上皮癌患者的Atezolizumab与化疗治疗比较 , moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=27af21101554)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1395039, encodeId=a2fe1395039e6, content=<a href='/topic/show?id=d1559341310' target=_blank style='color:#2F92EE;'>#转移性尿路上皮癌#</a>, objectTitle=Eur J Cancer：一线免疫检查点抑制剂联合疗法可明显改善转移性尿路上皮癌临床预后, objectType=article, longId=210997, objectId=424321099e06, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=424321099e06, replyNumber=0, likeNumber=76, createdTime=2021-05-10, rootId=0, userName=ms7019579240139182, userId=84182500174, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=424321099e06, moduleTitle=Eur J Cancer：一线免疫检查点抑制剂联合疗法可明显改善转移性尿路上皮癌临床预后, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=424321099e06)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1395038, encodeId=da271395038c9, content=<a href='/topic/show?id=d1559341310' target=_blank style='color:#2F92EE;'>#转移性尿路上皮癌#</a>, objectTitle=ESMO Open：抗PD-(L)1抗体治疗转移性尿路上皮癌的预后, objectType=article, longId=208783, objectId=b41c208e8335, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b41c208e8335, replyNumber=0, likeNumber=76, createdTime=2021-03-22, rootId=0, userName=ms7019579240139182, userId=84182500174, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b41c208e8335, moduleTitle=ESMO Open：抗PD-(L)1抗体治疗转移性尿路上皮癌的预后, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=b41c208e8335)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1395037, encodeId=49da139503e83, content=<a href='/topic/show?id=d1559341310' target=_blank style='color:#2F92EE;'>#转移性尿路上皮癌#</a>, objectTitle= Lancet oncol：PD-L1抑制剂Durvalumab±曲美单抗治疗转移性尿路上皮癌, objectType=article, longId=201131, objectId=a81a2011316b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a81a2011316b, replyNumber=0, likeNumber=119, createdTime=2020-09-25, rootId=0, userName=ms7019579240139182, userId=84182500174, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a81a2011316b, moduleTitle= Lancet oncol：PD-L1抑制剂Durvalumab±曲美单抗治疗转移性尿路上皮癌, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=a81a2011316b)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 风湿免疫小助手

转移性尿路上皮癌

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#转移性尿路上皮癌# #Trop-2# #戈沙妥珠单抗#

CLIN CANCER RES | Trop-2 在转移性尿路上皮癌患者中高表达，并可作为戈沙妥珠单抗治疗的潜在靶点

2024-08-09发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#EGFR突变# #转移性尿路上皮癌# #奥希替尼#

首例：携带EGFR突变的转移性尿路上皮癌获益奥希替尼五线治疗，获得长期缓解

2024-08-05发表于上海

侠胆医心 (审核中...)

前往app查看评论内容

全文收起在ARON-2真实世界研究(NCT05290038)的亚分析中，我们旨在评估同时使用#质子泵抑制剂#(PPI)、#他汀类药物#或#二甲双胍#对接受二线#帕博利珠单抗#治疗的#转移性尿路上皮癌#(mUC)患者预后的影响。这个解释从#肠道微生物#角度，有些存疑。使用PPI的人群，往往都伴有消化道疾病，或反酸，这会影响到患者的生活质量，这类患者可能对治疗本身应答也可能会产生影响，并不一定就是药物本身。同样，二甲双胍在不少观察性研究中显示对肿瘤免疫治疗可能有获益，但是#尿路上皮癌#治疗中，帕博利珠单抗的价值本身也有限，无法观察出协同效应也是正常的，但是并不代表在其它瘤种中有相似的结果。因此，在其它瘤种中，依然可以开展类似的研究，或进行meta分析

读书报告 | 应用帕博利珠单抗治疗转移性尿路上皮癌患者同时使用质子泵抑制剂、他汀类药物或二甲双胍对患者预后的影响

2024-02-23发表于加利福尼亚

梅斯管理员 (审核中...)

前往app查看评论内容

#伊匹单抗# #转移性尿路上皮癌# #纳武利尤单抗#

读书报告 | TITAN-TCC研究：含铂化疗后进展的尿路上皮癌患者接受定制的纳武利尤单抗联合伊匹木单抗免疫治疗的II期临床试验

2024-01-01发表于上海

ms7019579240139182 (审核中...)

前往app查看评论内容

#转移性尿路上皮癌#

J Clin Oncol：化疗后采用鲁卡帕尼维持治疗DNA修复缺陷阳性转移性尿路上皮癌

2022-08-18

ms7019579240139182 (审核中...)

前往app查看评论内容

#转移性尿路上皮癌#

Eur Urol：Bempegaldesleukin加Nivolumab用于一线转移性尿路上皮癌效果如何？

2022-06-27

ms7019579240139182 (审核中...)

前往app查看评论内容

#转移性尿路上皮癌#

J Clin Oncol：杜瓦鲁单抗联合奥拉帕利治疗初治的转移性尿路上皮癌的疗效和安全性

2022-06-26

ms7019579240139182 (审核中...)

前往app查看评论内容

#转移性尿路上皮癌#

J Immunother Cancer：卡瑞利珠单抗联合法米替尼治疗铂类进展的晚期或转移性尿路上皮癌的疗效和安全性

2022-05-13

ms7019579240139182 (审核中...)

前往app查看评论内容

#转移性尿路上皮癌#

NICE推荐Bavncio (avelumab)治疗局部晚期转移性尿路上皮癌 (UC)

2022-04-19

ms7019579240139182 (审核中...)

前往app查看评论内容

#转移性尿路上皮癌#

Eur Urol：恩福单抗维多汀治疗局部晚期或转移性尿路上皮癌的疗效如何？

2022-03-03

ms7019579240139182 (审核中...)

前往app查看评论内容

#转移性尿路上皮癌#

Clin Cancer Res：采用卡博替尼联合纳武单抗治疗PCI难治性转移性尿路上皮癌

2022-02-17

ms7019579240139182 (审核中...)

前往app查看评论内容

#转移性尿路上皮癌#

Clin Cancer Res：托瑞帕利单抗二线治疗转移性尿路上皮癌的疗效、安全性和生物标志物

2021-11-12

ms7019579240139182 (审核中...)

前往app查看评论内容

#转移性尿路上皮癌#

Int J Urol：铂基一线化疗对转移性尿路上皮癌患者总生存的影响

2021-10-24

ms7019579240139182 (审核中...)

前往app查看评论内容

#转移性尿路上皮癌#

The Oncologist：转移性尿路上皮癌铂类为基础化疗进展后再挑战的疗效

2021-08-10

ms7019579240139182 (审核中...)

前往app查看评论内容

#转移性尿路上皮癌#

Br J Cancer：转移性尿路上皮癌中FGFR3基因改变跟免疫检查点抑制剂应答的关系：真实世界研究

2021-07-30

heli0118 (审核中...)

前往app查看评论内容

#转移性尿路上皮癌#

Lancet oncol：Enfortumab vedotin用于抗PD-1治疗后的铂不适用的局部晚期或转移性尿路上皮癌的疗效可期！

2021-05-16

ms7019579240139182 (审核中...)

前往app查看评论内容

#转移性尿路上皮癌#

Eur Urol：铂治疗的局部晚期或转移性尿路上皮癌患者的Atezolizumab与化疗治疗比较

2021-05-11

ms7019579240139182 (审核中...)

前往app查看评论内容

#转移性尿路上皮癌#

Eur J Cancer：一线免疫检查点抑制剂联合疗法可明显改善转移性尿路上皮癌临床预后

2021-05-10

ms7019579240139182 (审核中...)

前往app查看评论内容

#转移性尿路上皮癌#

ESMO Open：抗PD-(L)1抗体治疗转移性尿路上皮癌的预后

2021-03-22

ms7019579240139182 (审核中...)

前往app查看评论内容

#转移性尿路上皮癌#

Lancet oncol：PD-L1抑制剂Durvalumab±曲美单抗治疗转移性尿路上皮癌

2020-09-25

科室
- - 订阅+
  - 更多科室
工具
服务